Thrombophilia: An Update

Saskia Middeldorp; Marcel Levi

doi:10.1055/s-2007-985752

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2007; 33(6): 563-572
DOI: 10.1055/s-2007-985752

Introduction

Thrombophilia: An Update

Saskia Middeldorp¹ , Marcel Levi²

¹Department of Clinical Epidemiology and Department of General Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands
²Department of Internal Medicine and Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Abstract

Full Text

References

REFERENCES

1 Levi M, Middeldorp S. Inherited thrombophilia. In: Young NS, Gerson SL, High KA Clinical Hematology. Philadelphia, PA; Elsevier 2006: 867-878
2 Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965; 13 516-530
3 Middeldorp S, Buller H R, Prins M H, Hirsh J. Approach to the thrombophilic patient. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA; Lippincott Williams & Wilkins 2001: 1085-1100
4 Halbmayer W M, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost. 1992; 68(3) 285-290
5 Koster T, Rosendaal F R, Briet E, Vandenbroucke J P. John Hagemann's factor and deep-vein thrombosis: Leiden Thrombophilia Study. Br J Haematol. 1994; 87(2) 422-424
6 Meltzer M E, Doggen C J, de Groot P G, Rosendaal F R, Lisman T. Fibrinolysis and the risk of venous and arterial thrombosis. Curr Opin Hematol. 2007; 14(3) 242-248
7 Ohlin A K, Marlar R A. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood. 1995; 85(2) 330-336
8 Heit J A, Petterson T M, Owen W G, Burke J P, DE Andrade M, Melton III L J. Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: a population-based case-control study. J Thromb Haemost. 2005; 3(4) 710-717
9 Sugiyama S, Hirota H, Kimura R et al.. Haplotype of thrombomodulin gene associated with plasma thrombomodulin level and deep vein thrombosis in the Japanese population. Thromb Res. 2007; 119(1) 35-43
10 Dahlback B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993; 90(3) 1004-1008
11 Bertina R M, Koeleman B P, Koster T et al.. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475) 64-67
12 Voorberg J, Roelse J, Koopman R et al.. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994; 343(8912) 1535-1536
13 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996; 88(10) 3698-3703
14 den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005; 3(2) 292-299
15 Ray J G, Shmorgun D, Chan W S. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb. 2002; 32(2) 51-58
16 Miletich J, Sherman L, Broze Jr G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987; 317(16) 991-996
17 Tait R C, Walker I D, Perry D J et al.. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 1994; 87(1) 106-112
18 Tait R C, Walker I D, Reitsma P H et al.. Prevalence of protein C deficiency in the healthy population. Thromb Haemost. 1995; 73(1) 87-93
19 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden. Lancet. 1995; 346(8983) 1133-1134
20 Ridker P M, Miletich J P, Hennekens C H, Buring J E. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997; 277(16) 1305-1307
21 Dilley A, Austin H, Hooper W C et al.. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med. 1998; 132(6) 452-455
22 Rosendaal F R, Doggen C J, Zivelin A et al.. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998; 79(4) 706-708
23 Bauer K A, Weiss L M, Sparrow D, Vokonas P S, Rosenberg R D. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest. 1987; 80(6) 1527-1534
24 Boisclair M D, Lane D A, Wilde J T, Ireland H, Preston F E, Ofosu F A. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol. 1990; 74(4) 471-479
25 Dewerchin M, Herault J P, Wallays G et al.. Life-threatening thrombosis in mice with targeted Arg48-to-Cys mutation of the heparin-binding domain of antithrombin. Circ Res. 2003; 93(11) 1120-1126
26 Levi M, Dorffler-Melly J, Reitsma P et al.. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003; 101(12) 4823-4827
27 Sanson B J, Simioni P, Prins M H. on behalf of the TACT-study group. The incidence of venous thromboembolism in asymptomatic carriers of a marker of thrombophilia. Blood. 1999; 94 3702-3706
28 Middeldorp S, Henkens C MA, Koopman M MW et al.. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med. 1998; 128(1) 15-20
29 Bank I, Libourel E J, Middeldorp S et al.. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med. 2004; 164(17) 1932-1937
30 Friederich P W, Sanson B J, Simioni P et al.. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 1996; 125 955-960
31 Pabinger I, Kyrle P A, Heistinger M et al.. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: a prospective cohort study. Thromb Haemost. 1994; 71(4) 441-445
32 Middeldorp S, Meinardi J R, Koopman M MW et al.. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med. 2001; 135(5) 322-327
33 Coppens M, van der Poel M H, Bank I et al.. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood. 2006; 108 2604-2607
34 Rosendaal F R. Venous thrombosis: a multicausal disease. Lancet. 1999; 353 1167-1173
35 Boekholdt S M, Bijsterveld N R, Moons A H, Levi M, Buller H R, Peters R J. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001; 104 3063-3068
36 Kim R J, Becker R C. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003; 146 948-957
37 Sanson B J, Friederich P W, Simioni P et al.. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost. 1996; 75(3) 387-388
38 Preston F E, Rosendaal F R, Walker I D et al.. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996; 348 913-916
39 Meinardi J R, Middeldorp S, de Kam P J et al.. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med. 1999; 130(9) 736-739
40 Rey E, Kahn S R, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet. 2003; 361 901-908
41 Dizon-Townson D S, Nelson L M, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol. 1996; 175(4 Pt 1) 902-905
42 van Pampus M G, Dekker G A, Wolf H et al.. High prevalence of haemostatic abnormalities in women with severe pre-eclampsia. Am J Obstet Gynecol. 1999; 180 1146-1150
43 Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol. 2002; 101 6-14
44 Middeldorp S. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications-No. J Thromb Haemost. 2003; 1 2073-2074
45 Middeldorp S. Low-molecular-weight heparin to prevent pre-eclampsia: there is no evidence and potential harm. Neth J Med. 2004; 62(3) 69-70
46 Brenner B. Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications-Yes. J Thromb Haemost. 2003; 1(10) 2070-2072
47 Di Nisio M, Peters L W, Middeldorp S. Anticoagulants for the treatment of recurrent pregnancy loss in women without antiphospholipid syndrome. Cochrane Database Syst Rev. 2005; (2) , CD004734
48 Branson H E, Katz J, Marble R, Griffin J H. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet. 1983; 2 1165-1168
49 Broekmans A W, Bertina R M, Loeliger E A, Hofmann V, Klingemann H G. Protein C and the development of skin necrosis during anticoagulant therapy. Thromb Haemost. 1983; 49 251
50 Vink R, Kraaijenhagen R A, Levi M, Buller H R. Individualised duration of oral anticoagulant therapy for deep vein thrombosis based on a decision model. J Thromb Haemost. 2003; 1(12) 2523-2530
51 Cohn D M, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost. 2007; 33 573-581
52 Rosendaal F R, Koster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995; 85(6) 1504-1508
53 Greengard J S, Eichinger S, Griffin J H, Bauer K A. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg- > Gln mutation in the gene for factor V. N Engl J Med. 1994; 331(23) 1559-1562
54 Emmerich J, Alhenc-Gelas M, Aillaud M F et al.. Clinical features in 36 patients homozygous for the ARG 506- > GLN factor V mutation. Thromb Haemost. 1997; 77(4) 620-623
55 Meinardi J R, Pelsma P, Koning H et al.. Double-homozygosity for factor V Leiden and the prothrombin gene 20210A variant in a young patient with idiopathic venous thrombosis. Blood. 1999; 94 1828-1829
56 Koeleman B P, Reitsma P H, Allaart C F, Bertina R M. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994; 84(4) 1031-1035
57 Koeleman B P, van Rumpt D, Hamulyak K, Reitsma P H, Bertina R M. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families?. Thromb Haemost. 1995; 74(2) 580-583
58 Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlback B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood. 1995; 85(12) 3518-3523
59 Meinardi J R, Middeldorp S, de Kam P J et al.. Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect. Blood Coagul Fibrinolysis. 2001; 12(8) 713-720
60 Meinardi J R, Middeldorp S, de Kam P J et al.. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol. 2002; 116(3) 625-631
61 Libourel E J, Bank I, Meinardi J R et al.. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. Haematologica. 2002; 87 1068-1073
62 Anonymous. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995; 346(8990) 1575-1582
63 Daly E, Vessey M P, Painter R, Hawkins M M. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet. 1996; 348(9033) 1027
64 Jick H, Derby L E, Myers M W, Vasilakis C, Newton K M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996; 348(9033) 981-983
65 Kemmeren J M, Algra A, Grobbee D E. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001; 323 131-134
66 Vandenbroucke J P, Koster T, Briet E, Reitsma P H, Bertina R M, Rosendaal F R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994; 344(8935) 1453-1457
67 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Buller H R, Vandenbroucke J P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995; 346(8990) 1593-1596
68 Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand. 1983; 62(3) 239-243
69 Greer I A. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 1999; 353(9160) 1258-1265
70 Conard J, Horellou M H, van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990; 63(2) 319-320
71 De Stefano V, Leone G, Mastrangelo S et al.. Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost. 1994; 71(6) 799-800
72 Simioni P, Sanson B J, Prandoni P et al.. The incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost. 1999; 81(2) 198-202
73 Middeldorp S, Libourel E J, Hamulyak K, van der M J, Buller H R. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol. 2001; 113(2) 553-555
74 Kearon C. Natural history of venous thromboembolism. Circulation. 2003; 107(23suppl 1) I22-I30
75 Prandoni P, Lensing A W, Cogo A et al.. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996; 125(1) 1-7
76 Van Dongen C JJ, Vink R, Hutten B A, Buller H R, Prins M H. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event. A meta-analysis. Arch Intern Med. 2003; 163 1285-1293
77 Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden: cost-effectiveness analysis. Thromb Haemost. 2000; 84 752-757
78 Ho W K, Hankey G J, Quinlan D J, Eikelboom J W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006; 166(7) 729-736
79 Margaglione M, D'Andrea G, Colaizzo D et al.. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost. 1999; 82(6) 1583-1587
80 Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci P M. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol. 2000; 111(4) 1223-1229
81 Kraaijenhagen R A, in 't Anker P S, Koopman M MW, Reitsma P H, Prins M H, Buller H R. High plasma concentration of factor VIIIc: a major risk factor for venous thromboembolism. Thromb Haemost. 2000; 83(1) 5-9
82 Kyrle P A, Minar E, Hirschl M et al.. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000; 343(7) 457-462
83 Buller H R, Agnelli G, Hull R D, Hyers T M, Prins M H, Raskob G E. Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 401S-428S
84 Geerts W H, Pineo G F, Heit J A et al.. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 suppl) 338S-400S
85 Nurmohamed M T, Rosendaal F R, Buller H R et al.. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992; 340 152-156
86 Warkentin T E, Levine M N, Hirsh J et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 332(20) 1330-1335
87 Bates S M, Greer I A, Hirsh J, Ginsberg J S. Use of antithrombotic agents during pregnancy. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004; 126(suppl) 627S-644S
88 Sanson B J, Lensing A WA, Prins M H et al.. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999; 81 668-672
89 Pabinger I, Grafenhofer H, Kaider A et al.. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005; 3(5) 949-954
90 Christiansen S C, Cannegieter S C, Koster T, Vandenbroucke J P, Rosendaal F R. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005; 293(19) 2352-2361
91 Koster T, Small R A, Rosendaal F R, Helmerhorst F M. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med. 1995; 238(1) 31-37
92 Anonymous. Cardiovascular disease and use of oral and injectable progestagen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. 1998; 57(5) 315-324
93 Gladson C L, Scharrer I, Hach V, Beck K H, Griffin J H. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost. 1988; 59(1) 18-22
94 Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost. 1989; 61(1) 50-54
95 Schattner A, Kasher I, Berrebi A. Causes and outcome of deep-vein thrombosis in otherwise-healthy patients under 50 years. QJM. 1997; 90(4) 283-287
96 O'Donnell J, Tuddenham E G, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost. 1997; 77(5) 825-828
97 Heijboer H, Brandjes D P, Buller H R, Sturk A, ten Cate J W. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med. 1990; 323(22) 1512-1516
98 Pabinger I, Brucker S, Kyrle P A et al.. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis. 1992; 3(5) 547-553
99 Koster T, Rosendaal F R, Briet E et al.. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995; 85(10) 2756-2761
100 Koster T, Rosendaal F R, de Ronde H, Briet E, Vandenbroucke J P, Bertina R M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993; 342(8886-8887) 1503-1506
101 Cumming A M, Keeney S, Salden A, Bhavnani M, Shwe K H, Hay C R. The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population. Br J Haematol. 1997; 98(2) 353-355
102 Brown K, Luddington R, Williamson D, Baker P, Baglin T. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene. Br J Haematol. 1997; 98 907-909